Bispecific Antibody Binding CD3 and SLAMF6 for Selective T-Cell Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for modulating T-cell activity are limited in their ability to effectively target and regulate T-cell responses, particularly through the SLAMF6 co-receptor, which is crucial for immunomodulation.

Innovation Solution

Development of bispecific antibodies that can bind to both CD3, CD45, or CD43 proteins and SLAMF6, either clustering or localizing SLAMF6 to modulate T-cell activity, enhancing T-cell function by promoting or disrupting signaling pathways.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If monospecific antibodies are used to target T-cell receptors, then T-cell activation can be achieved, but the ability to selectively modulate T-cell responses through co-receptors like SLAMF6 is limited

Engineering Contradiction:

Improveability to modulate T-cell responsesVSAvoidantibody structure complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent combines two antibody specificities into a single bispecific antibody molecule that can simultaneously bind to CD3 (or CD45/CD43) and SLAMF6. This merging approach enables the antibody to engage both the T-cell receptor complex and the SLAMF6 co-receptor, thereby selectively modulating T-cell responses with enhanced adaptability while maintaining a unified molecular structure rather than using separate antibodies

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The bispecific antibody is designed to perform multiple functions: it can activate T-cells through CD3 binding while simultaneously modulating the response through SLAMF6 engagement. This multi-functionality allows a single antibody molecule to regulate T-cell activity in a more nuanced and adaptable manner compared to monospecific antibodies, addressing the versatility requirement without proportionally increasing complexity

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Productivity

If SLAMF6 is targeted to enhance T-cell activation, then cytokine secretion and T-cell function are improved, but specificity in targeting particular T-cell responses may be reduced

Engineering Contradiction:

ImproveT-cell function and cytokine secretionVSAvoidtargeting specificity

Core Design Contradiction:

ProductivityVSMeasurement precision

Solution Approach 1:

The bispecific antibody employs local quality by differentiating between activating and inhibitory antibody arms. The CD3-binding arm provides activation while the SLAMF6-binding arm provides selective modulation. This local differentiation within the single antibody molecule enables enhanced T-cell function through cytokine secretion while maintaining specificity for particular T-cell responses through the selective SLAMF6 engagement

Inventive Principle:

Principle #3Local quality

3Reliability

If bispecific antibodies are designed to bind both CD3 and SLAMF6, then the ability to cluster or localize SLAMF6 is enhanced, but the complexity of antibody production and characterization increases

Engineering Contradiction:

ImproveSLAMF6 clustering and localization capabilityVSAvoidantibody production complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent merges the functionality of two separate antibodies into one bispecific antibody molecule, which simultaneously binds CD3 and SLAMF6. This consolidation enhances the reliability of SLAMF6 clustering and localization capability by ensuring coordinated engagement of both targets from a single molecular entity, while the unified structure actually simplifies certain aspects of production compared to coordinating two separate antibodies

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20250320294A1Bispecific antibody for t-cell modulation

Publication Date: 2025.10.16 THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

AI summary

The subject matter described here relates to bispecific antibodies capable of modulating T-cell activity, wherein the two arms of the bispecific antibody are against CD3 and SLAMF6, against CD45 and SLAMF6, or against CD43 and SLAMF6.